Advertisement
111, Inc.

111, Inc. Fundamental Analysis

YINASDAQ
HealthcareMedical - Pharmaceuticals
$4.97
$0.69(16.12%)
U.S. Market opens in 64h 44m
Advertisement

111, Inc. Fundamental Analysis

111, Inc. (YI) shows moderate financial fundamentals with a PE ratio of -3.44, profit margin of -0.66%, and ROE of 13.93%. The company generates $11.3B in annual revenue with N/A year-over-year growth of N/A.

Key Strengths

Cash Position160.44%
PEG Ratio0.02

Areas of Concern

Operating Margin-0.24%
We analyze YI's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of 50.7/100 based on profitability, valuation, growth, and balance sheet metrics. The C grade reflects average fundamentals, with notable risks in certain areas.

Fundamental Health Score

C
50.7/100

We analyze YI's fundamental strength across five key dimensions:

Efficiency Score

Weak

YI struggles to generate sufficient returns from assets.

ROA > 10%
-26.90%

Valuation Score

Excellent

YI trades at attractive valuation levels.

PE < 25
-3.44
PEG Ratio < 2
0.02

Growth Score

Weak

YI faces weak or negative growth trends.

Revenue Growth > 5%
N/A
EPS Growth > 10%
N/A

Financial Health Score

Excellent

YI maintains a strong and stable balance sheet.

Debt/Equity < 1
-0.38
Current Ratio > 1
1.08

Profitability Score

Weak

YI struggles to sustain strong margins.

ROE > 15%
13.93%
Net Margin ≥ 15%
-0.66%
Positive Free Cash Flow
No

Key Financial Metrics

Is YI Expensive or Cheap?

P/E Ratio

YI trades at -3.44 times earnings. This suggests potential undervaluation.

-3.44

PEG Ratio

When adjusting for growth, YI's PEG of 0.02 indicates potential undervaluation.

0.02

Price to Book

The market values 111, Inc. at -2.43 times its book value. This may indicate undervaluation.

-2.43

EV/EBITDA

Enterprise value stands at -14.74 times EBITDA. This is generally considered low.

-14.74

How Well Does YI Make Money?

Net Profit Margin

For every $100 in sales, 111, Inc. keeps $-0.66 as profit after all expenses.

-0.66%

Operating Margin

Core operations generate -0.24 in profit for every $100 in revenue, before interest and taxes.

-0.24%

ROE

Management delivers $13.93 in profit for every $100 of shareholder equity.

13.93%

ROA

111, Inc. generates $-26.90 in profit for every $100 in assets, demonstrating efficient asset deployment.

-26.90%

Following the Money - Real Cash Generation

Operating Cash Flow

111, Inc. generates limited operating cash flow of $2.62M, signaling weaker underlying cash strength.

$2.62M

Free Cash Flow

111, Inc. generates weak or negative free cash flow of $-12.47M, restricting financial flexibility.

$-12.47M

FCF Per Share

Each share generates $-1.43 in free cash annually.

$-1.43

FCF Yield

YI converts -4.89% of its market value into free cash.

-4.89%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-3.44

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

0.02

vs 25 benchmark

P/B Ratio

Price to book value ratio

-2.43

vs 25 benchmark

P/S Ratio

Price to sales ratio

0.02

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

-0.38

vs 25 benchmark

Current Ratio

Current assets to current liabilities

1.08

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

0.14

vs 25 benchmark

ROA

Return on assets percentage

-0.27

vs 25 benchmark

ROCE

Return on capital employed

-0.85

vs 25 benchmark

How YI Stacks Against Its Sector Peers

MetricYI ValueSector AveragePerformance
P/E Ratio-3.4434.27 Better (Cheaper)
ROE13.93%377.00% Weak
Net Margin-0.66%-42945.00% (disorted) Weak
Debt/Equity-0.380.78 Strong (Low Leverage)
Current Ratio1.085.54 Neutral
ROA-26.90%-162.00% (disorted) Weak

YI outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews 111, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

N/A

Industry Style: Defensive, Growth, Innovation

EPS CAGR

N/A

Industry Style: Defensive, Growth, Innovation

FCF CAGR

N/A

Industry Style: Defensive, Growth, Innovation

Fundamental Analysis FAQ